Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Increases By 816.4%

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 91,267 shares, an increase of 816.4% from the June 15th total of 9,959 shares. Based on an average daily volume of 194,642 shares, the short-interest ratio is presently 0.5 days. Approximately 2.5% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pulmatrix currently has an average rating of “Sell”.

Pulmatrix Trading Down 4.4%

Shares of NASDAQ PULM traded down $0.08 during midday trading on Friday, hitting $1.72. 46,122 shares of the company’s stock were exchanged, compared to its average volume of 109,360. Pulmatrix has a 12-month low of $1.16 and a 12-month high of $6.83. The company has a market cap of $6.28 million, a price-to-earnings ratio of -1.40 and a beta of 1.90. The business’s fifty day moving average price is $1.45 and its two-hundred day moving average price is $1.89.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new stake in Pulmatrix stock. DRW Securities LLC acquired a new stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).